Kurz gefasst
Übersichtsarbeit in der Zeitschrift PET Clinics, 2026. Verfasst von Harshad R Kulkarni. Beteiligte Einrichtung: BAMF Health, 109 Michigan Street NW, Suite 700, Grand Rapids, MI 49503, USA. Electronic address: harshad.kulkarni@bamfhealth.com. Hauptthemen laut MEDLINE: Precision Medicine, Radiopharmaceuticals, Molecular Imaging, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Theranostics in nuclear medicine has traditionally referred to pairing a diagnostic scan with a matched radiopharmaceutical therapy. This review argues for a broader, target-centric framework. In this model, molecular imaging serves as an in vivo companion diagnostic that verifies target expression across the whole body and guides selection, initiation, and monitoring of targeted therapies. This paradigm extends beyond radiopharmaceutical therapy to include antibody-drug conjugates, immunotherapy, and endocrine therapy. As precision medicine evolves, theranostics is best understood as a clinical pathway linking target biology to treatment decisions through imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BAMF Health, 109 Michigan Street NW, Suite 700, Grand Rapids, MI 49503, USA. Electronic address: harshad.kulkarni@bamfhealth.com.
Zitieren
APA
Kulkarni, H. R. (2026). Theranostics. PET Clinics. https://doi.org/10.1016/j.cpet.2026.03.003
Vancouver
Kulkarni HR. Theranostics. PET Clinics. 2026. doi:10.1016/j.cpet.2026.03.003
BibTeX
@article{Kulkarni2026,
author = {Kulkarni, Harshad R},
title = {Theranostics},
journal = {PET Clinics},
year = {2026},
doi = {10.1016/j.cpet.2026.03.003}
}
EUVIMED